N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 1 ClinicalTrials.gov

A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

Sponsor: Eli Lilly and Company • ClinicalTrials.gov ID: NCT07571174

Registry updated: 2026-09-22
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The main purpose of this study is to assess the long-term safety and tolerability of LY4256984 in participants with Amyotrophic Lateral Sclerosis (ALS). This study is a long-term extension of study J6I-MC-OWAA (NCT07100119) and is part of the OLMP (NCT07571200) master protocol that will last approximately 96 weeks.

Interventions

  • LY4256984 (Drug)
    Administered IT

Eligibility criteria

Participants must meet eligibility criteria in the \[L0U-MC-OLMP\] screening protocol before entry into the treatment study. Inclusion Criteria: * Have completed the main treatment period/phase as well as any off-treatment period/phase of Study OWAA, the parent study for this ISA. Exclusion Criteria: * The participant has conditions that preclude a lumbar puncture (LP), such as: * A history of clinically significant back pain, back pathology, and/or back injury (for example, degenerative disease, spinal deformity, or spinal surgery) that may predispose to complications or technical difficulty with LP. * Allergy to local anesthetics, such as lidocaine or its derivatives. * A local infection at the intended site of the LP. * Less than 100 giga per liter \[(\<100 GI/L) is equivalent to 100,000 per cubic millimeter (100,000/mm³)\] platelets or clinically significant coagulation abnormality or significant active bleeding, or * Currently receiving treatment with an anticoagulant, antiplatelet agent, or other drug that affects coagulation or platelet function. Low dose (according to local medical guidelines) aspirin is permitted.

Conditions

Amyotrophic Lateral Sclerosis

Locations

  • UZ Leuven — Leuven, Belgium
  • Heritage Medical Research Clinic — Calgary, Canada
  • University Hospital - London Health Sciences Centre — London, Canada
  • McGill University Health Centre — Montreal, Canada
  • Sunnybrook Research Institute — Toronto, Canada
  • Universitätsklinikum Schleswig-Holstein — Lübeck, Germany
  • Universitätsmedizin Rostock — Rostock, Germany
  • Universitaetsklinikum Ulm — Ulm, Germany
  • Universitair Medisch Centrum Utrecht — Utrecht, Netherlands
  • Hospital Universitari de Bellvitge — L'Hospitalet de Llobregat, Spain
  • Hospital Universitari i Politecnic La Fe — Valencia, Spain
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record